[] with 1. 100mmol not able to be mmol/24hr Supine: calculated as medication tablets/day (p<0.001) SBP: -1mmHg insufficient data in paper 2. Placebo tablets (SEM: 3.49, CI: 5.84) The study did not prescribe a diet, DBP: (SEM: and assumed that 2.96, CI: -4.80, participants 6.80) continued their usual diet throughout Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to Use of Ceasing study Reporting all Funding randomisation concealment early for benefit outcome source where results required Carney et Unclear risk (no Unclear risk (no Participants: 0% (low risk) Not required No (low risk) Unclear risk Not stated al. (1991) description of description of low risk (low risk) (Insufficient (unclear risk) method of method of data on (company Providers: low sequence concealment of standing BP to supplied risk generation) allocation) calculate) capsules but no indication Outcome of funding) assessors: unclear risk
[] with medication 1. 100mmol tablets/day 2. Placebo tablets The study did not prescribe a diet, and assumed that participants continued their usual diet throughout not able to be calculated as insufficient data in paper mmol/24hr (p<0.001) Supine: SBP: -1mmHg (SEM: 3.49, CI: 5.84) DBP: (SEM: 2.96, CI: -4.80, 6.80) Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to Use of where required Ceasing study early for benefit Reporting all outcome results Funding source Carney et al. (1991) Unclear risk (no description of method of sequence generation) Unclear risk (no description of method of concealment of allocation) Participants: low risk Providers: low risk Outcome assessors: unclear risk 0% (low risk) Not required (low risk) No (low risk) Unclear risk (Insufficient data on standing BP to calculate) Not stated (unclear risk) (company supplied capsules but no indication of funding)
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx